These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35158055)

  • 1. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease.
    Zou B; Odden MC; Nguyen MH
    Clin Gastroenterol Hepatol; 2023 Feb; 21(2):435-444.e6. PubMed ID: 35158055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
    Pinyopornpanish K; Al-Yaman W; Butler RS; Carey W; McCullough A; Romero-Marrero C
    Am J Gastroenterol; 2021 Nov; 116(11):2258-2269. PubMed ID: 34212895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Case-control Study.
    German MN; Lutz MK; Pickhardt PJ; Bruce RJ; Said A
    J Clin Gastroenterol; 2020 Sep; 54(8):733-740. PubMed ID: 31567625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease.
    Lee TY; Wu JC; Yu SH; Lin JT; Wu MS; Wu CY
    Int J Cancer; 2017 Oct; 141(7):1307-1314. PubMed ID: 28509327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins Are Associated With a Decreased Risk of Severe Liver Disease in Individuals With Noncirrhotic Chronic Liver Disease.
    Sharma R; Simon TG; Hagström H; Lochhead P; Roelstraete B; Söderling J; Verna EC; Emond J; Ludvigsson JF
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):749-759.e19. PubMed ID: 37121528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis.
    Hsiang JC; Wong GL; Tse YK; Wong VW; Yip TC; Chan HL
    J Hepatol; 2015 Nov; 63(5):1190-7. PubMed ID: 26208777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
    Simon TG; Duberg AS; Aleman S; Hagstrom H; Nguyen LH; Khalili H; Chung RT; Ludvigsson JF
    Ann Intern Med; 2019 Sep; 171(5):318-327. PubMed ID: 31426090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study.
    Huang DQ; Tran S; Barnett S; Zou B; Yeo YH; Cheung R; Nguyen MH
    Hepatol Int; 2024 Apr; 18(2):540-549. PubMed ID: 38079023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statin can reduce the risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Zhang J; Fu S; Liu D; Wang Y; Tan Y
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):353-358. PubMed ID: 36719824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
    Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
    Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
    Goh MJ; Sinn DH; Kim S; Woo SY; Cho H; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Hepatology; 2020 Jun; 71(6):2023-2032. PubMed ID: 31556128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
    Chen J; Song S; Li X; Bian D; Wu X
    Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis.
    Petrelli F; Manara M; Colombo S; De Santi G; Ghidini M; Mariani M; Iaculli A; Rausa E; Rampulla V; Arru M; Viti M; Lonati V; Ghidini A; Luciani A; Facciorusso A
    Neoplasia; 2022 Aug; 30():100809. PubMed ID: 35636146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Course and Outcomes of Patients with Nonalcoholic Fatty Liver Disease-Related Hepatocellular Cancer (NAFLD-HCC).
    Chu J; Cholankeril G; Yu X; Rana A; Natarajan Y; El-Serag HB; Kramer J; Kanwal F
    Dig Dis Sci; 2023 Mar; 68(3):1060-1070. PubMed ID: 35759159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of statin treatment with hepatocellular carcinoma risk in end-stage kidney disease patients with chronic viral hepatitis.
    Kim HW; Joo YS; Kang SC; Koh HB; Han SH; Yoo TH; Kang SW; Park JT
    Sci Rep; 2022 Jun; 12(1):10807. PubMed ID: 35752695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.
    Simon TG; Bonilla H; Yan P; Chung RT; Butt AA
    Hepatology; 2016 Jul; 64(1):47-57. PubMed ID: 26891205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitutions of saturated fat intakes with other macronutrients and foods and risk of NAFLD cirrhosis and all-cause hepatocellular carcinoma: a prospective cohort study.
    Fridén M; Warensjö Lemming E; Lind L; Vessby J; Rosqvist F; Risérus U
    Am J Clin Nutr; 2024 Jul; 120(1):187-195. PubMed ID: 38797249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
    Golabi P; Rhea L; Henry L; Younossi ZM
    Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.